Ann: PAR Appoints Business Development Consultant, page-147

Mozzarc great to hear from you again. CSL have had a monumental failure in their hoped for new drug to prevent reinfarction in 3 months following a cardiac infarction. $1.5b US down the drain. It’s a very long shot but perhaps Scott Williams could contact CSL and sell the IPPS story to them. They could come on board for a mere $100m down payment. They can then partake in a sure thing, pain relief, even though it’s not a vascular drug , sorry it has some anti coagulation properties. Hope springs eternal. See what blockbuster drugs did for NOVO NORDISK, 2 to 3 times the size of BHP and Europes biggest company.